North America Continuous Glucose Monitoring Market size to cross USD 22.6 Billion by 2034

Selbyville, DE. - North America continuous glucose monitoring market was estimated at USD 5.1 billion in 2024 and is expected to grow from USD 5.9 billion in 2025 to USD 22.6 billion by 2034, at a CAGR of 16.1%, according to the latest report published by Global Market Insights Inc.  

North America has one of the highest rates of diabetes globally, particularly Type 2 diabetes. The increasing diabetic population fuels demand for CGM systems as they provide real-time monitoring and better glycemic control, reducing complications.  

Key Insights:

Market Size & Growth:

• 2024 Market Size: USD 5.1 billion
• 2025 Market Size: USD 5.9 billion
• 2034 Forecast Market Size: USD 22.6 billion
• CAGR (2025–2034): 16.1%  

Regional Insights:

• Largest Market: U.S.
• Fastest Growing Market: Canada  

Key Growth Drivers:

1. Technological advancements in CGM devices: Recent innovations such as longer sensor lifespans, reduced calibration requirements, smartphone integration, and non-invasive solutions are making CGM devices more user-friendly and effective, leading to broader adoption.  
2. Favorable reimbursement policies: Both the U.S. and Canada have increasingly included CGM systems in public and private insurance plans, making them more accessible to patients and encouraging market growth.  
3. Growing awareness of preventive healthcare: There is a growing consumer and physician focus on proactive diabetes management rather than reactive treatment.  
4. Increasing adoption of digital health and remote monitoring: Post-COVID, there’s a strong push toward remote patient monitoring and telehealth.  
5. Strong presence of key market players: Major medical device companies like Dexcom, Abbott, and Medtronic are headquartered or have a significant presence in North America.  

Key Players:

• Dexcom led the market with over 53.4% share in 2024.  
• Some of the top players in this market include Senseonics, Medtronic, F. Hoffmann-La Roche, Abbott Laboratories, Dexcom, which together held a 99.9% share in 2024.  

Key Challenges:

1. High cost of devices and sensors: CGM systems and their consumables remain expensive, limiting access for uninsured or underinsured patients.  
2. Reimbursement gaps and insurance limitations: While coverage has improved, inconsistencies in reimbursement policies still act as a barrier for advanced features or newer models.  
3. User compliance and device fatigue: Some users find continuous use of wearable sensors inconvenient or uncomfortable, leading to decreased adherence over time.  
4. Data privacy and security concerns: With increasing digital connectivity, concerns over patient data protection and cybersecurity risks are becoming more prominent.  
5. Technical limitations and accuracy issues: Though improving, CGMs can still have accuracy issues, especially in extreme blood glucose ranges, leading to potential trust issues.  

Browse key industry insights spread across 90 pages with 40 market data tables and figures from the report, “North America Continuous Glucose Monitoring Market Size - By Component, By End Use, Growth Forecast, 2025 - 2034” in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/north-america-continuous-glucose-monitoring-market  

Growing Adoption of CGM Sensors

The sensors segment accounted for a significant share in 2024. These sensors are essential for capturing real-time glucose levels from interstitial fluid and transmitting accurate data to devices or smartphone applications. As users seek enhanced comfort, longer wear duration, and minimal calibration requirements, manufacturers are focusing on advancing sensor technology. Innovations such as extended wear sensors, flexible materials, and pre-calibrated solutions are fueling this segment’s expansion. The upward trend underscores a broader movement toward user convenience, particularly for individuals managing diabetes outside of traditional healthcare facilities.  

Increasing shift toward homecare settings

The homecare segment is expected to experience steady growth between 2025 and 2034, driven by a rising preference for remote monitoring and self-managed care. Patients are increasingly turning to CGM systems to track glucose levels in real time from the comfort of their homes. These systems not only support daily disease management but also enable seamless data sharing with healthcare providers and family members through connected digital platforms. This trend is minimizing the need for frequent clinical visits and empowering individuals to take a more proactive and independent role in their diabetes care.  

U.S. to Emerge as a Lucrative Region

U.S. continuous glucose monitoring (CGM) market held a significant share in 2024, driven by rising diabetes prevalence, growing patient awareness, and strong technology adoption across healthcare systems. With the Centers for Disease Control and Prevention (CDC) estimating over 37 million Americans living with diabetes, the demand for real-time glucose monitoring solutions is escalating. Market leaders are responding to this need with next-generation CGM devices that offer extended sensor life, smartphone compatibility, and seamless integration with insulin delivery systems. Market growth is further supported by favorable reimbursement policies, consumer demand for personalized healthcare, and a significant shift toward home-based and remote monitoring technologies.  

Major players involved in the North America continuous glucose monitoring market are i-SENS, Glucovation, Medtronic, Nemaura Medical, F. Hoffmann-La Roche, Dexcom, A. Menarini Diagnostics, Senseonics, Abbott Laboratories, Insulet Corporation, and Sinocare.  

Companies competing in the North America CGM market are focusing on innovation, partnerships, and patient-centric solutions to strengthen their market position. Strategic collaborations with digital health platforms, pharmacy chains, and insurance providers are helping major players expand reach and accessibility. Many firms are investing heavily in R&D to develop non-invasive or minimally invasive CGM solutions that improve comfort and accuracy while reducing maintenance. Mergers and acquisitions remain a favored strategy for expanding product portfolios and gaining a competitive edge.